brassinolide has been researched along with cyc 202 in 1 studies
Studies (brassinolide) | Trials (brassinolide) | Recent Studies (post-2010) (brassinolide) | Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) |
---|---|---|---|---|---|
598 | 0 | 306 | 979 | 7 | 393 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Arısan, ED; Coker Gurkan, A; Kara, M; Obakan Yerlikaya, P; Okumus, OO; Ozbey, U; Palavan Unsal, N; Yenigun, T | 1 |
1 other study(ies) available for brassinolide and cyc 202
Article | Year |
---|---|
Epibrassinolide prevents tau hyperphosphorylation via GSK3β inhibition in vitro and improves Caenorhabditis elegans lifespan and motor deficits in combination with roscovitine.
Topics: Animals; Brassinosteroids; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Drug Therapy, Combination; Glycogen Synthase Kinase 3 beta; Longevity; Motor Disorders; Neuroprotective Agents; Phosphorylation; Plant Growth Regulators; Protein Kinase Inhibitors; Roscovitine; Steroids, Heterocyclic; tau Proteins | 2021 |